Colony-stimulating factor 1 receptor (CSF1R) inhibition has been proposed to specifically deplete microglia without affecting peripheral immune cells. Here, we show that CSF1R inhibition by PLX5622 causes changes in the myeloid and lymphoid compartments and longterm functional impairment of bone marrow-derived macrophages by suppressing their IL-1β expression, phagocytosis, and M1, but not M2 phenotype. Thus, CSF1R inhibition with small
molecule inhibitors is not restricted to microglia only, but rather causes strong effects on peripheral macrophages that perdure long after cessation of the treatment. These changes may have significant implications on the interpretation of relevant experimental data. \body Colony stimulating factor 1 receptor (CSF1R) inhibition has been proposed as a specific microglia depletion method (1-3) that does not affect peripheral immune cells (2, (4) (5) (6) . However, this argument has been solely based on cell count measurements of blood monocytes and evaluation of blood brain barrier rather than direct assessment of cellular subtypes and their function. Given that peripheral monocytes are known to participate in CNS disease (6) (7) (8) (9) (10) (11) (12) and in the repopulation of microglia following their depletion, (10, 12) it is important to definitively determine if CSF1R inhibition affects the function of peripheral immune cells (3, 5, 6, (12) (13) (14) (15) .
Here we show that, contrary to the accepted notion,(2, 3) PLX5622, a commonly used small molecule CSF1R inhibitor for microglia depletion, (3, 10, 12) leads to long-term changes in the myeloid and lymphoid compartments of the bone marrow and spleen by suppressing CCR2 + monocyte progenitor cells, CX3CR1 + bone marrow-derived macrophages (BMDM), CD117 + (C-KIT +) hematopoietic progenitor cells, and CD34 + hematopoietic stem cells, and Ly6G neutrophils CSF1R inhibition also suppresses bone marrow-derived lymphoid CD3 + , CD4 + , and CD8 + cells with a previous study that showed recombinant CSF1-Fc protein to induce M1-like macrophage phenotype, but not M2 (16, 17) .
In conclusion, this study provides compelling evidence that CSF1R inhibition by PLX5622 does not simply deplete microglial cells, but also affects the myeloid and lymphoid compartments and causes functional impairment in BMDMs. Considering the role of peripheral monocytes in CNS disease, (9, 10) this work suggests that microglia depletion studies with small molecule inhibitors are not specific to microglia but additionally affect the number and function of peripheral macrophages, and these effects perdure long after cessation of the treatment and may have significant implications on the interpretation of relevant experimental data. PLX5622 was kindly provided by Plexxikon Inc. 
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